Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib and Momelotinib in Relapsed/Refractory FLT3-Mutated AML
NCT06235801Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mivavotinib in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events at 1 year, Minimum safe and biologically-effective dose at 1 year and 1 more. Started May 2024; status: recruiting.
02
Drugs
mivavotinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06235801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235801.